1
TÍTULO: Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2-advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2,-3, and-7 trials  Full Text
AUTORES: Hart, Lowell L.; Im, Seock Ah; Tolaney, Sara M.; Campone, Mario; Pluard, Timothy; Sousa, Berta; Freyer, Gilles; Decker, Thomas; Kalinsky, Kevin; Sopher, Gary; Gao, Melissa; Hu, Huilin; Kuemmel, Sherko;
PUBLICAÇÃO: 2025, FONTE: EUROPEAN JOURNAL OF CANCER, VOLUME: 217
INDEXADO EM: Scopus WOS
2
TÍTULO: XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
AUTORES: Schmid, Peter; Cortes, Javier; Joaquim, Ana; Janez, Noelia Martinez; Morales, Serafin; Diaz Redondo, Tamara; Blau, Sibel; Neven, Patrick; Lemieux, Julie; Garcia Saenz, Jose Angel; Hart, Lowell; Biyukov, Tsvetan; Baktash, Navid; Massey, Dan; Burris, Howard A., III; Rugo, Hope S.;
PUBLICAÇÃO: 2023, FONTE: BREAST CANCER RESEARCH, VOLUME: 25, NÚMERO: 1
INDEXADO EM: Scopus WOS